Zevra launches MIPLYFFA for NPC; early adoption ahead of expectations

ZEVRA THERAPEUTICS, INC.

MIPLYFFA (arimoclomol) commercially available at Zevra's specialty pharmacy; first FDA-approved NPC treatment.
Early adoption exceeded expectations; launch within 8–12 weeks post-approval as previously guided.
Indicated in combination with miglustat for neurological NPC in patients aged 2+.
AmplifyAssist patient support program launched to address insurance and access barriers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.